AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01186315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure therapy + VR/ER
Description: The therapy includes repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories and adding in virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use \& CER used outside treatment sessions in response to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use
Study NCT04853056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: wearing virtual reality glasses
Study NCT01837394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg tablet as needed in the postoperative period after discharge from the PACU
Study NCT01837394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide
Description: 10 mg tablet as needed in the postoperative period after discharge from the PACU
Study NCT01006577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: side-to-end anastomosis
Description: Low anterior resection for rectal cancer \< 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
Study NCT01006577 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: colon j pouch
Description: Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
Study NCT04853056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold vibration
Description: Buzzy
Study NCT02897076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone 24 mg
Study NCT02897076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 12mg betamethasone +placebo
Study NCT02392234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-661/Ivacaftor
Description: Fixed dose combination tablet, oral use
Study NCT02392234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Tablet, oral use
Study NCT02392234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to VX-661/ ivacaftor
Description: Fixed dose combination tablet, oral use
Study NCT02392234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to VX-661/ ivacaftor
Description: Fixed dose combination tablet, oral use
Study NCT03976193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BfitBwell program
Description: Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
Study NCT03976193 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BfitBwell program
Description: Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
Study NCT03976193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6 bi-weekly PA Behavior Change counseling sessions
Description: Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
Study NCT01208818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Bortezomib + Dexamethasone regimen
Description: Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~* Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect.
Study NCT01208818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib +Dexamethasone regimen
Description: Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect.
Study NCT01208818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib +Dexamethasone regimen
Description: Dosing regimen (21 day-cycle):~* Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~* Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect.
Study NCT02392234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to Ivacaftor
Description: Tablet, oral use
Study NCT02392234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matched to Ivacaftor
Description: Tablet, oral use
Study NCT01426412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014 IV
Description: Administered IV over 30-90 minutes
Study NCT01426412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Administered IV only over 30-90 minutes
Study NCT01426412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3015014 SC
Description: Administered SC
Study NCT01426412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Administered SC
Study NCT01762059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-homonal Bionic Pancreas
Description: A computer algorithm will automatically deliver insulin lispro and glucagon based on the signal from a minimally invasive continuous glucose monitor.
Study NCT01762059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study NCT00044564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bay 59-8862
Description: 75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
Study NCT02029235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/Ibuprofen
Description: Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free
Study NCT02029235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen/Hydrocodone
Description: Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
Study NCT02142751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin sodium intravenous
Description: 4g every 6 hours iv (60 min infusion)
Study NCT02142751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem intravenous
Description: 1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
Study NCT02142751 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ceftriaxone intravenous
Description: 1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
Study NCT00281892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fludarabine plus Darbopoetin
Description: Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
Study NCT00281892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine mono
Description: Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa.
Study NCT04556981 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M72/AS01E Mycobacterium tuberculosis vaccine
Description: Participants will receive an intramuscular dose of M72 (10 micrograms of recombinant fusion protein) reconstituted with AS01E (an adjuvant system), on Day 1 and Day 29
Study NCT04556981 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive an intramuscular dose of saline (0.9% NaCl), on Day 1 and Day 29
Study NCT00386945 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief counseling (Ask, Advise, Arrange)
Description: Providers are trained to provide Ask, Advise and Arrange (brief cessation counseling) to all tobacco using patients. A Fax-to-Quit referral to a tobacco quit line and written materials on local cessation resources and pharmacotherapy are provided.
Study NCT03945578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor muscle training - PFMT
Description: Pelvic Floor muscle training is an active exercise-based treatment designed to strengthen the pelvic floor muscles. The PFMT protocol was divided into four phases. Proprioceptive (2 weeks): where the woman has gained adequate perception of PFM and control of fast and slow contractions; Simple (1 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (1 week): where the exercise evolved into functional exercises of greater amplitude; and Power (1 week): where the control of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and for fast fibers (the list of exercises and a detailed description of them is in Appendix 1).
Study NCT04452201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Participation
Description: GP couples' participation together in development of communication competencies in the context of infant care will be supported by a handbook and telephone guidance structured for collaboration with the nurse/research assistant beginning at approximately 2 weeks of age. Two face-to-face sessions are expected prior to hospital discharge, followed by 5 or 6 monthly phone sessions. If the baby is inpatient at the time an intervention session is to take place, the session may be done face-to-face, if more convenient than a phone session for the parents.
Study NCT04595305 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac resynchronization therapy by CRT-P or CRT-D implantation
Description: Clinically indicated implantation of a CRT-P or CRT-D device as per standard of care
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet adherence
Description: This type of intervention is to be established in a-posteriori analysis by the assessment of a fact whether a subject kept to use his usual diet or it contained substantial changes.
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: diet adherence
Description: This type of intervention is to be established in a-posteriori analysis by the assessment of a fact whether a subject kept to use his usual diet or it contained substantial changes.
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No diet adherence
Description: A-posteriori established intervention based on the examinations at the end-point
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No diet adherence
Description: A-posteriori established intervention based on the examinations at the end-point
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in physical activity
Description: The changes in physical activity will be assessed a-posteriori based on the examination at the end-point versus baseline data
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Change in physical activity
Description: The changes in physical activity will be assessed a-posteriori based on the examination at the end-point versus baseline data
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No change in physical activity
Description: The changes in physical activity will be assessed a-posteriori based on the examination at the end-point and comparison to the baseline data
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No change in physical activity
Description: The changes in physical activity will be assessed a-posteriori based on the examination at the end-point and comparison to the baseline data
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of antisecretory agents
Description: This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data. The need for the use of anti-secretory agents depends on the form of GERD and will be on the treating physician discretion. It is principal to account the use of anti-secretory agents (H2-histamine receptors blockers, proton pump inhibitors) as a major factors that may influence the outcomes.
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Use of antisecretory agents
Description: This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data. The need for the use of anti-secretory agents depends on the form of GERD and will be on the treating physician discretion. It is principal to account the use of anti-secretory agents (H2-histamine receptors blockers, proton pump inhibitors) as a major factors that may influence the outcomes.
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No use of antisecretory agents
Description: This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data.
Study NCT04255693 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No use of antisecretory agents
Description: This intervention will be established a-posteriori, based on the examination at the end-point and compared to the baseline data.
Study NCT01472510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
Study NCT01472510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
Study NCT04240613 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TVT-O
Description: TVT-O is one of the most popular treatments for urinary incontinence (UI). Its efficacy is well established in patients with pure stress urinary incontinence (SUI). Data reporting long-term outcomes of TVT-O for the treatment of mixed urinary incontinence (MUI) or recurrent SUI is scarce. The objective of this study was to evaluate the efficacy and safety and overall patient satisfaction of TVT-O in different subgroups of UI in a long-term follow-up.
Study NCT02215707 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
Study NCT03387709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pistachio-enriched diet
Description: Composition of prescribed diets will be based on individual preferences, with the goal of consuming 1.5 oz of pistachios per day and increased energy expenditure. During the 4-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Pistachios will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
Study NCT03387709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General dietary guidance diet
Description: During the 4-month group intervention, study subjects will participate group sessions, receive telephone, email and/or text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
Study NCT01332591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Description: PCI of significant stenoses of non-infarct coronary arteries
Study NCT01574820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo tablet for 6 months
Study NCT01574820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg)/day
Description: rosiglitazone (4 mg)/day for 6 months
Study NCT04381052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Description: Dose is 25mg intravenously over 30 minutes.
Study NCT03945578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor muscle training - PFMT
Description: Pelvic Floor muscle training is an active exercise-based treatment designed to strengthen the pelvic floor muscles. The PFMT protocol was divided into four phases. Proprioceptive (2 weeks): where the woman has gained adequate perception of PFM and control of fast and slow contractions; Simple (1 week): performed with the objective of promoting control of fast and slow contractions associated with small functional exercises; Elaborated (1 week): where the exercise evolved into functional exercises of greater amplitude; and Power (1 week): where the control of the pelvic floor was promoted during efforts. In all sessions, contractions were performed for slow and for fast fibers (the list of exercises and a detailed description of them is in Appendix 1).
Study NCT03945578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visceral Manual Therapy - VMT
Description: Visceral manual therapy:is a manual treatment intended to the release of visceral fascias. The VMT protocol was based on the work proposed by Vanderheyden-Busquet (2014). To act on the abdominal and pelvic visceral fasciae, the VMT was performed through slow and deep mobilizations, respecting the participant's tissue resistance and painful response, in different regions of the abdômen.
Study NCT04381052 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenously administered over 30 minutes.
Study NCT05392673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KM-8800 plasma exchange device (Kuraray, Tokyo, Japan)
Description: Artificial liver scavenges inflammatory factors.
Study NCT02840318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion Intervention
Description: See arm description
Study NCT04434430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Oral Gabapentin 600 mg
Study NCT04434430 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral NaCl 500 mg
Study NCT03945578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Sham Therapy - MST
Description: The manual sham therapy protocol was perfomed by gentle techniques applied to the thoracic spine, scapular waist and cervical spine